Wing Capital Partners, wholly owned by Ashikaga Bank, and Nagase Future Investments, wholly owned by Nagase and Co., Ltd., invested through the CVC funds they operate. Craif did not disclose the amount.
TOKYO, June 10, 2025 - Craif Inc., a bio-AI company developing a urine analysis platform for early detection of cancer and other diseases, said it has raised additional capital in a Series C extension round from two corporate venture capital funds.
The funds are operated by Wing Capital Partners, Inc. of Utsunomiya, Tochigi, a wholly owned subsidiary of Ashikaga Bank, Ltd., and by Nagase Future Investments, Inc. of Chiyoda, Tokyo, a wholly owned subsidiary of the trading company Nagase and Co., Ltd. Craif is headquartered in Bunkyo ward, Tokyo, and is led by CEO Ryuichi Onose.
The round is an extension of Craif's existing Series C, not a new round.
Use of proceeds
Craif said the proceeds will fund further research and development on the miSignal urine cancer risk test, clinical development of its medical device software program, and detection technology for diseases beyond its current tests. The company also said it will strengthen its research and development organization in the United States, with FDA approval and insurance reimbursement in view, in order to accelerate its expansion outside Japan.
Where the company stands
Craif was founded in 2018 as a Nagoya University spin-off, working on early disease detection and treatment optimization with the goal of a society in which people live out their natural lifespan. The company was among the first to work on practical applications of microRNA, the subject of the 2024 Nobel Prize in Physiology or Medicine, and developed technology that uses AI to analyze microRNA in urine. That work underpins miSignal Scan, which is intended to enable very early detection of risk for hard-to-treat cancers, such as pancreatic and lung cancer.
At the time of Craif's Series B in October 2021, miSignal Scan was still in development. Since its launch in February 2022, the test has been taken up by more than 1,000 medical institutions and more than 500 drugstores and pharmacies across Japan, and has grown through corporate employee benefit programs and e-commerce channels. Including research use, Craif has accumulated more than 42,000 specimen data records and has reported in approximately 60 academic papers and conference reports. Most recently, the company reported findings on early, high-precision detection of pancreatic cancer in eClinicalMedicine, a journal in the Lancet family.
Craif's clinical testing laboratory, licensed by the responsible local authority in Japan, has doubled its floor area and increased analytical capacity by more than 15 times. In April 2024, the company began a clinical trial aimed at Japanese regulatory approval of a medical device software program for pancreatic cancer diagnosis.
Craif has set up a research and development laboratory in Irvine, California, and plans to open a business office in San Diego. It has begun collecting pancreatic cancer specimens with 30 medical institutions across 15 states, and is building up its US research and development with FDA approval and insurance reimbursement as the objective.
Investor comments
Mitsushige Ishigaki, Representative Director, Wing Capital Partners, Inc.:
"As part of the Ashikaga Bank group, we invest in a range of venture companies with the aim of developing the regional economy. Craif is working on a urine test that uses microRNA in urine to support early detection of cancer."
Nagase Future Investments, Inc.:
"We are very glad to have the chance to invest in Craif, a company whose innovative technology makes possible the early detection of cancers with very poor prognosis, something existing testing technology has not achieved."
About the miSignal Series
The miSignal Series is a set of cancer risk tests aimed at prevention and early detection. It includes miSignal Scan, which assesses cancer risk using microRNA and AI; miSignal Lite, a simpler cancer risk assessment; miSignal Navi, a genetic test focused on cancer; and miSignal Check, which monitors DNA damage as an input to prevention. Every test in the series requires only a urine or saliva sample and places no physical burden on the person tested.
The miSignal Series products are not medical devices. They assess risk through statistical calculations based on analyzed information. They do not replace diagnosis of cancer as a medical act, and a low risk result does not mean that cancer is absent or that the person will not develop cancer in the future.
About Craif
Craif is a bio-AI company founded in 2018 that develops non-invasive tests for the early detection of cancer. Its platform combines proprietary biomarker detection from urine and other bodily fluids with AI to assess disease risk. Building on one of the world's largest urine datasets, Craif aims to create a urine analysis platform that detects a wide range of diseases early, with cancer as the first step. The company is based in Tokyo and operates a wholly owned laboratory in San Diego, opened in 2026. Learn more at craif.com.